Symptomatic management of the neurological, renal and pulmonary manifestations of tuberous sclerosis is essential

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.25, Iss.6, 2009-06, pp. : 13-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Management of Tuberous Sclerosis Complex

By Krueger Darcy A. Franz David N.

Pediatric Drugs, Vol. 10, Iss. 5, 2008-01 ,pp. : 299-313

Adis International

Access to resources Recommend Favorite

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex: A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin

By > Hebert Adelaide A. Roberson Joan

Drugs in R&D, Vol. 12, Iss. 3, 2012-09 ,pp. : 121-126

Adis International

Access to resources Recommend Favorite

Bosentan: A Review of its Use in the Management of Mildly Symptomatic Pulmonary Arterial Hypertension

By Dhillon Sohita Keating Gillian M.

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 5, 2009-10 ,pp. : 331-350

Adis International

Access to resources Recommend Favorite

Tuberous sclerosis presenting with confusion and agitation

By Konda Shruthi

Clinical Medicine, Vol. 11, Iss. 5, 2011-10 ,pp. : 502-503

Royal College Of Physicians

Access to resources Recommend Favorite

mTOR Inhibitors in Tuberous Sclerosis Complex

Current Neuropharmacology, Vol. 10, Iss. 4, 2012-12 ,pp. : 404-415

Bentham Science Publishers

Access to resources Recommend Favorite